Cytosorbents (NASDAQ:CTSO) is a biotherapeutics company focused on the development and commercialization of blood purification technologies designed to remove harmful substances from the bloodstream. Its proprietary hemoadsorption platform employs polymer beads that selectively bind and clear inflammatory mediators, toxins, and metabolic waste. The company’s flagship product, CytoSorb, is indicated for use in a range of critical care settings, including sepsis, systemic inflammatory response syndrome (SIRS), cardiac surgery, and various forms of organ support therapy.
CytoSorb operates as a single-use cartridge that can be integrated into existing extracorporeal circuits, such as dialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO) systems. The technology’s broad binding profile targets cytokines, bilirubin, myoglobin, and other middle‐molecular‐weight substances implicated in organ dysfunction. Cytosorbents continuously refines its product pipeline by exploring new indications, optimizing cartridge design, and advancing platform applications in areas such as anti‐drug overdose and intraoperative blood management.
Founded in 2005 and headquartered in Princeton, New Jersey, Cytosorbents has established a global footprint, with its flagship hemoadsorption therapy available in more than 75 countries. The company holds CE Mark approval in Europe and has received Breakthrough Device designation from the U.S. Food and Drug Administration, positioning CytoSorb for expanded commercialization in North America. Cytosorbents also maintains strategic partnerships and distributor agreements across Asia, Latin America, and the Middle East to accelerate market adoption and generate real-world clinical data.
The executive leadership team combines expertise in critical care medicine, nephrology, immunology, and medical device development. With a management team experienced in product development, regulatory affairs, and global commercialization, Cytosorbents continues to pursue clinical trials and health economic studies aimed at broadening its therapeutic impact. The board of directors comprises seasoned professionals in biotechnology investment, hospital procurement, and translational research, providing strategic guidance as the company advances its mission to transform critical care through blood purification.
